MARKET

GLPG

GLPG

Galapagos
NASDAQ

Real-time Quotes | Nasdaq Last Sale

69.22
-2.51
-3.50%
Pre Market: 68.16 -1.06 -1.53% 04:21 06/24 EDT
OPEN
70.77
PREV CLOSE
71.73
HIGH
71.02
LOW
69.16
VOLUME
32
TURNOVER
--
52 WEEK HIGH
214.36
52 WEEK LOW
69.16
MARKET CAP
4.54B
P/E (TTM)
-13.9994
1D
5D
1M
3M
1Y
5Y
Pain Relief Therapeutics Market 2021 Opportunity Assessment, Business Opportunities, Top Industry Players, Trend and Growth to 2027
Heraldkeepers · 7h ago
14 Biotech Stocks To Watch Over The Next 6 Months
Biotechs are at the mercy of several make-or-break catalysts that invariably have a big impact on stocks.
Benzinga · 15h ago
The Daily Biotech Pulse: Gemini Sinks On Data, Amgen's Migraine Drug Approved In Japan, Liver Congress Gets Underway
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 22)
Benzinga · 20h ago
Galapagos announces departure of CSO Piet Wigerinck later this year
Mechelen, Belgium; 22 June 2021, 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announces the departure of Dr. Piet Wigerinck later this year.
Globe Newswire · 1d ago
Galapagos Chief Scientific Officer to Leave Company Later This Year
MT Newswires · 1d ago
BRIEF-Galapagos NV Says Co Increases Share Capital Through Subscription Right Exercises
reuters.com · 06/07 20:05
Galapagos increases share capital through subscription right exercises
Mechelen, Belgium; 7 June 2021, 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises.
Globe Newswire · 06/07 20:01
Galapagos, Gilead's Selection study on filgotinib in ulcerative colitis published in the Lancet
Results from Galapagos' (GLPG) Phase 3 SELECTION induction and maintenance study were published in The Lancet.The study, sponsored by Gilead Sciences (GILD) was designed to assess the efficacy and safety
Seekingalpha · 06/04 10:18
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GLPG. Analyze the recent business situations of Galapagos through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GLPG stock price target is 92.54 with a high estimate of 117.23 and a low estimate of 67.56.
EPS
Institutional Holdings
Institutions: 220
Institutional Holdings: 8.49M
% Owned: 12.96%
Shares Outstanding: 65.52M
TypeInstitutionsShares
Increased
48
1.95M
New
38
979.76K
Decreased
25
562.77K
Sold Out
19
260.01K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.36%
Pharmaceuticals & Medical Research
-0.51%
Key Executives
Chairman - Management/Chief Executive Officer/Executive Director
Onno van de Stolpe
Non-Executive Chairman
Raj Parekh
Non-Executive Chairman
Rajesh Parekh
Chief Financial Officer/Chief Operating Officer/Executive Board
Bart Filius
Chief Scientific Officer/Executive Board
Piet Wigerinck
Vice President/IR Contact Officer
Elizabeth Goodwin
Executive Board
Walid Abi-Saab
Executive Board
Andre Hoekema
Non-Executive Independent Director
Katrine Bosley
Non-Executive Independent Director
Werner Cautreels
Non-Executive Director
Harrold van Barlingen
Non-Executive Independent Director
Mary Kerr
Non-Executive Independent Director
Christine Mummery
No Data
About GLPG
Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is focused on the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company aims to develop a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. In addition, the Company’s mission is to develop a number of medicines based on the discovery of novel targets. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. Galapagos aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease.

Webull offers kinds of Galapagos NV stock information, including NASDAQ:GLPG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GLPG stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GLPG stock methods without spending real money on the virtual paper trading platform.